Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Recent & Breaking News (GREY:IMVIQ)

IMV Inc. to Present at Upcoming Investor Conferences

Business Wire August 22, 2019

IMV Inc. Announces Second Quarter 2019 Financial Results and Provides Company Update

Business Wire August 8, 2019

IMV Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference

Business Wire July 26, 2019

IMV Inc. to Announce Second Quarter 2019 Results and Host a Conference Call and Webcast on August 9, 2019

Business Wire July 25, 2019

IMV Inc. to Present at Two Upcoming Investor Conferences

Business Wire June 13, 2019

New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV's DPX-Survivac in Combination with Merck's Keytruda in Patients with DLBCL

Business Wire June 12, 2019

IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019

Business Wire June 4, 2019

IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival

Business Wire June 1, 2019

IMV Inc. to Present at Upcoming Investor Conferences

Business Wire May 14, 2019

IMV Announces Annual and Special Meeting of Shareholders Voting Results

Business Wire May 10, 2019

IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances

Business Wire May 9, 2019

IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019

Business Wire May 8, 2019

IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck's Keytruda® in DLBCL

Business Wire May 3, 2019

IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019

Press Releases April 26, 2019

IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019

Business Wire April 26, 2019

IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors

Press Releases April 18, 2019

IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors

Business Wire April 18, 2019

IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update

Press Releases April 16, 2019

IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update

Business Wire April 16, 2019

IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference

Business Wire April 4, 2019